Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma
A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients With Refractory or Recurrent Neuroblastoma
Sponsor: Giselle Sholler
This NA trial investigates Neuroblastoma and is currently completed. Giselle Sholler leads this study, which shows 10 recorded versions since 2011 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
May 2024 — Jul 2024 [monthly]
Completed NA
-
Oct 2023 — May 2024 [monthly]
Completed NA
▶ Show 5 earlier versions
-
May 2022 — Oct 2023 [monthly]
Completed NA
-
Jan 2021 — May 2022 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Feb 2017 — Jun 2018 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
May 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Giselle Sholler
For direct contact, visit the study record on ClinicalTrials.gov .